BIA: UK pricing uncertainty causing companies to rethink drug launches
This article was originally published in Scrip
Continued uncertainty over an overhaul of the UK's pricing and reimbursement regime is making companies rethink their launch sequences for new products and is putting investors off the UK as a top place to conduct clinical development, so says Steve Bates, CEO of BioIndusrtry Association.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.